多诺万利什曼原虫Th1刺激蛋白对实验性内脏利什曼病的免疫治疗潜力
研究评估四种Th1刺激重组蛋白(醛缩酶、烯醇化酶、p45和磷酸丙糖异构酶)在利什曼原虫感染仓鼠中的免疫治疗潜力,以不同剂量(50、25和12.5 μg/只)免疫动物。较低剂量的醛缩酶和烯醇化酶(25和12.5 μg)使寄生虫负荷显著下降约60%,并增强细胞免疫应答。结果表明这些Th1刺激蛋白免疫治疗对实验性内脏利什曼病有效,但联合已知治疗方案或免疫调节剂可能进一步提高疗效。
要点
- 醛缩酶和烯醇化酶低剂量(25和12.5 μg/只)使感染仓鼠寄生虫负荷下降约60%。
- 上述低剂量免疫同时增强了细胞免疫应答。
- 作者认为联合已知治疗方案或免疫调节剂可能进一步提高疗效。
核心结论
- 用上述Th1刺激蛋白免疫是抗实验性内脏利什曼病的有效免疫治疗方法。
- 作者认为联合已知治疗方案或免疫调节剂可能进一步提高疗效。
研究设计与样本
- 在利什曼原虫感染仓鼠中评估四种Th1刺激重组蛋白(醛缩酶、烯醇化酶、p45和磷酸丙糖异构酶)的免疫治疗潜力,动物以不同剂量(50、25和12.5 μg/只)免疫。
主要发现
- 较低剂量醛缩酶和烯醇化酶(25和12.5 μg/只)免疫使寄生虫负荷显著下降约60%,并伴随细胞免疫应答增强。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An effective therapeutic vaccination strategy is required for controlling visceral leishmaniasis (VL), a fatal systemic disease, through boosting the immunosuppressed state in Leishmania-infected individuals, as the majority of them living in the endemic regions exhibit either subclinical or asymptomatic infection which further often develops into a full-blown disease. Previously in our laboratory, several Th1 stimulatory recombinant proteins were successfully cloned, purified and assessed for their prophylactic efficacy against Leishmania challenge. Due to their immunostimulatory property, these proteins are needed to be evaluated for their immunotherapeutic potential in Leishmania-infected hamsters. Four proteins namely, aldolase, enolase, p45 and triose phosphate isomerase were taken up to immunize animals at different doses (50, 25 and 12.5 μg/animal). Immunization with lower doses of aldolase and enolase, i.e., 25 and 12.5 μg showed a significant decline (∼60%) in parasitic load along with an enhanced cellular immune response. These findings indicate that vaccination with above -stated Th1 stimulatory proteins is an effective immunotherapeutic approach against experimental VL. However, their efficacies may further be improved in combination with known therapeutic regimens or immunomodulators.
引用
- Keerti, Yadav NK, Joshi S, et al. Immunotherapeutic potential of Leishmania (Leishmania) donovani Th1 stimulatory proteins against experimental visceral leishmaniasis. Vaccine. 2018. PMID: 29573875. doi:10.1016/j.vaccine.2018.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。